The upregulation of tumor suppressors miR-30C, and miR-107 and the downregulation of oncogenic factors like miR-25, IL-6 and C-Myc aligns with established targets for anticancer therapy, suggesting potential clinical relevance. This evidence concerns the gene IL6 and neoplasm.